Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
This randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma.
The purpose of this study is to determine the event-free survival (EFS) and overall survival (OS) of children with completely resected ependymoma treated with maintenance chemotherapy comprising vincristine sulfate, cisplatin, etoposide, and cyclophosphamide (VCEC) versus observation following post-operative conformal radiotherapy (cRT).
- IRB Number: 1106005970 (PHO-COG-FALLON-ACNS0831)
- Research Study Identifier: TX500
- Principal Investigator: Batra Sandeep, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required